AnaptysBio, Inc. (ANAB) Ownership
ANAB ownership summary
as of October 17, 2026- Institutions
- 105.3% of shares outstanding
- Insiders
- 5.63% of shares outstanding
- Shares outstanding
- 29.9M
- Float
- 20.4M shares available to trade
- Short interest
- 38.53% 5.2M shares short
- Days to cover
- 8.96 short interest down 3.7% vs prior month
- Institutions 105.29%
- Insiders 5.63%
ANAB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 26.36% | 7.9M | $367.3M | — | June 30, 2026 |
| 2 | BlackRock Inc | 6.17% | 1.8M | $86.0M | +162,669 (+9.7%) | June 30, 2026 |
| 3 | TANG CAPITAL MANAGEMENT LLC | 4.45% | 1.3M | $62.0M | — | June 30, 2026 |
| 4 | State Street Corp | 4.30% | 1.3M | $59.9M | +293,749 (+29.6%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.03% | 906K | $42.2M | +53,082 (+6.2%) | June 30, 2026 |
| 6 | Affinity Asset Advisors, LLC | 2.76% | 826K | $38.5M | −113,891 (−12.1%) | June 30, 2026 |
| 7 | Sanofi | 2.75% | 822K | $38.3M | — | June 30, 2026 |
| 8 | Millennium Management LLC | 2.70% | 807K | $37.6M | +331,744 (+69.8%) | June 30, 2026 |
| 9 | Woodline Partners LP | 2.40% | 717K | $33.4M | +372,758 (+108.3%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.13% | 638K | $29.7M | +117,632 (+22.6%) | June 30, 2026 |
| 11 | 683 Capital Management LLC | 2.09% | 625K | $29.1M | −23,093 (−3.6%) | March 31, 2026 |
| 12 | Palo Alto Investors, LLC | 2.02% | 603K | $28.1M | −34,672 (−5.4%) | June 30, 2026 |
| 13 | The Goldman Sachs Group Inc | 1.95% | 584K | $27.2M | +251,327 (+75.5%) | June 30, 2026 |
| 14 | First Light Asset Management, LLC | 1.95% | 582K | $27.1M | +16,573 (+2.9%) | June 30, 2026 |
| 15 | D. E. Shaw & Co LP | 1.81% | 540K | $25.2M | −39,630 (−6.8%) | June 30, 2026 |
| 16 | Vanguard Portfolio Management, LLC | 1.77% | 528K | $24.6M | +7,988 (+1.5%) | June 30, 2026 |
| 17 | Apis Capital Advisors, LLC | 1.66% | 497K | $23.2M | +259,000 (+108.8%) | June 30, 2026 |
| 18 | Sofinnova Ventures | 1.65% | 494K | $23.0M | +245,283 (+98.8%) | June 30, 2026 |
| 19 | Arrowstreet Capital Limited Partnership | 1.63% | 489K | $22.8M | −3,469 (−0.7%) | June 30, 2026 |
| 20 | Nuveen, LLC | 1.41% | 421K | $19.6M | +104,599 (+33.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 2.2M shares and 5 cut 215K.
ANAB top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.17% | 648K | $30.2M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.16% | 645K | $30.0M | −12,300 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 1.75% | 522K | $24.3M | −6,016 (−1.1%) | September 30, 2026 |
| 4 | Nuveen Quant Small Cap Equity R6 | 0.73% | 219K | $10.2M | −44,900 (−17.0%) | August 31, 2026 |
| 5 | Fidelity Small Cap Index | 0.72% | 216K | $10.1M | +2,101 (+1.0%) | July 31, 2026 |
| 6 | iShares Biotechnology ETF | 0.72% | 216K | $10.1M | −1,632 (−0.8%) | September 30, 2026 |
| 7 | Federated Hermes Kaufmann Small Cap A | 0.70% | 210K | $9.8M | −80,000 (−27.6%) | June 30, 2026 |
| 8 | Invesco Biotechnology & Genome ETF | 0.67% | 201K | $9.4M | — | September 30, 2026 |
| 9 | Victory Science & Technology | 0.63% | 188K | $8.8M | — | June 30, 2026 |
| 10 | iShares Russell 2000 Growth ETF | 0.63% | 187K | $8.7M | −237 (−0.1%) | September 30, 2026 |
| 11 | Burney U.S. Equity Select ETF | 0.50% | 150K | $7.0M | +118 (+0.1%) | September 30, 2026 |
| 12 | Fidelity Advisor Biotechnology I | 0.50% | 148K | $6.9M | — | March 31, 2026 |
| 13 | First Trust Small Cap Gr AlphaDEX® ETF | 0.48% | 143K | $6.6M | +252 (+0.2%) | September 30, 2026 |
| 14 | Vanguard Strategic Equity Inv | 0.44% | 131K | $6.1M | +131,265 (0.0%) | June 30, 2026 |
| 15 | Burney U.S. Factor Rotation ETF | 0.43% | 129K | $6.0M | +122 (+0.1%) | September 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.38% | 114K | $5.3M | +2,639 (+2.4%) | August 31, 2026 |
| 17 | Schwab US Small-Cap ETF™ | 0.38% | 113K | $5.3M | +72 (+0.1%) | September 30, 2026 |
| 18 | Vanguard Explorer Inv | 0.38% | 112K | $5.2M | +14,154 (+14.4%) | June 30, 2026 |
| 19 | Federated Hermes MDT Small Cap Core IS | 0.36% | 106K | $5.0M | +70,195 (+194.6%) | June 30, 2026 |
| 20 | Fidelity Extended Market Index | 0.33% | 100K | $4.7M | −1,047 (−1.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ANAB insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-30 | John P Schmid | Sell | $56.11 | 20,645 | $1.2M |
| 2026-03-27 | Daniel Faga | Sell | $61.61 | 17,679 | $1.1M |
| 2026-02-11 | Eric J Loumeau | Sell | $54.00 | 10,000 | $540,000 |
| 2026-01-15 | Magda Marquet | Sell | $48.23 | 11,000 | $530,530 |
| 2026-01-08 | Daniel Faga | Sell | $44.71 | 14,281 | $638,504 |
| 2026-01-08 | Dennis Mulroy | Sell | $44.71 | 2,515 | $112,446 |
| 2026-01-08 | Eric J Loumeau | Sell | $44.71 | 2,210 | $98,809 |
| 2026-01-08 | Paul F Lizzul | Sell | $44.71 | 3,650 | $163,192 |
| 2026-01-07 | Daniel Faga | Sell | $45.11 | 9,202 | $415,102 |
| 2026-01-07 | Dennis Mulroy | Sell | $45.11 | 1,908 | $86,070 |
| 2026-01-07 | Eric J Loumeau | Sell | $45.56 | 9,639 | $439,153 |
| 2026-01-07 | Paul F Lizzul | Sell | $45.11 | 2,235 | $100,821 |
| 2026-01-05 | Daniel Faga | Sell | $43.26 | 15,309 | $662,267 |
| 2026-01-05 | Paul F Lizzul | Sell | $43.26 | 4,219 | $182,514 |
| 2026-01-05 | Eric J Loumeau | Sell | $43.26 | 2,983 | $129,045 |
| 2026-01-05 | Dennis Mulroy | Sell | $43.26 | 3,363 | $145,483 |
| 2025-12-23 | J. Anthony Ware | Sell | $49.58 | 3,900 | $193,362 |
| 2025-12-22 | Dennis Mulroy | Sell | $50.00 | 10,000 | $500,000 |
| 2025-12-22 | Eric J Loumeau | Sell | $51.00 | 10,000 | $510,000 |
| 2025-12-22 | Paul F Lizzul | Sell | $50.00 | 1,500 | $75,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ANAB shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ANAB
Institutional investors own 105.3% of AnaptysBio's shares and insiders 5.63%. The largest holder is EcoR1 Capital, LLC with 26.36% of the shares (7.9M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 5 reduced their stake in the latest filings. Short interest is 38.53% of the float, or 8.96 days of average trading volume. The share count rose 1,163.3% since 2014.
Related: ANAB analyst forecast, ANAB key metrics. See the ANAB stock overview for the latest quote and news.
ANAB ownership FAQ
Who owns the most AnaptysBio stock?
The largest shareholders of AnaptysBio are EcoR1 Capital, LLC (26.36%), BlackRock Inc (6.17%), TANG CAPITAL MANAGEMENT LLC (4.45%), State Street Corp (4.30%), Vanguard Capital Management, LLC (3.03%).
What percentage of AnaptysBio is owned by institutions?
Institutions hold 105.3% of AnaptysBio's shares outstanding; insiders hold 5.63%.
Which funds own AnaptysBio?
The largest fund holders of AnaptysBio are Vanguard MStar Total Stk Mkt Idx Invest (2.17%), State Street® SPDR® S&P® Biotech ETF (2.16%), iShares Russell 2000 ETF (1.75%), Nuveen Quant Small Cap Equity R6 (0.73%), Fidelity Small Cap Index (0.72%).
What is AnaptysBio's short interest?
5.2M shares of AnaptysBio were sold short, 38.53% of the float; at the average daily volume it would take 8.96 days to cover.
Are insiders buying or selling AnaptysBio?
Of the latest 20 reported insider transactions in AnaptysBio (since December 22, 2025), 0 were purchases and 20 were sales.
How many shares of AnaptysBio are outstanding?
AnaptysBio has 29.9M shares outstanding, of which 20.4M are in the public float.